TAB1 and colorectal carcinoma: By inhibiting the expression of JMJD8, TNF receptor-related factor 5 (TRAF5) and TGF-β activated kinase 1 (MAP3K7) binding protein 1 (TAB1), miR-873-5p can inhibit the NF-κβ signaling pathway, thereby hindering the progression of CRC (6, 45).